Overall survival for patients harboring T315I mutated leukemias. (A) OS analysis for patients with CML in CP (bold solid line), AP (bold dashed line), or blast crisis (thin solid line) or with de novo Ph⁺ ALL (thin dashed line) since T315I ABL mutation detection who underwent allogeneic SCT. (B) OS analysis for patients with CML in CP (bold solid line), AP (AccP; bold dashed line), or blast crisis (BC; thin solid line) or with de novo Ph⁺ ALL (thin dashed line) since T315I ABL mutation detection in the overall cohort of patients with T315I mutation (Figure 2D in Nicolini et al² ) compared with panel A. (C) OS analysis for patients with CML in CP (bold solid line), AP (bold dashed line), or blast crisis (thin solid line) or with de novo Ph⁺ ALL (thin dashed line) since allogeneic SCT according to disease status at transplantation. Median OS has not been reached for CP and AP and was 10.3 months for BP (range 5.7 months to not reached) and 7.4 months for Ph⁺ ALL (range 1.4 months to not reached).